OneMedNet Corporation Price & Performance (ONMD)

OneMedNet Corporation faces potential delisting from Nasdaq after failing to meet multiple listing requirements, including a $35 million market value threshold and $2.5 million in stockholders’ equity. The company has until September 8, 2025, to address these issues or risk delisting. Strategic efforts are underway to rectify the situation.1

OneMedNet has partnered with Datavant to enhance access to tokenized healthcare data. This collaboration integrates OneMedNet’s extensive network of 31 million patients with Datavant’s ecosystem, enabling improved patient journey analysis and accelerating evidence-based healthcare solutions. The initiative aims to maintain privacy while bolstering data connectivity and research efficiency.2

Dr. Kenneth Alleyne, a seasoned orthopedic surgeon, has been appointed to OneMedNet's board. Serving as Audit Committee Chair, Alleyne brings expertise in healthcare and governance. His addition is expected to strengthen corporate oversight and foster innovation in orthopedic and insurance sectors, enhancing the company’s strategic direction.3